(3Z)-3-[(E)-(5-methylfuran-2-yl)methylidenehydrazinylidene]-1-pyridin-4-ylindol-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (3Z)-3-[(E)-(5-methylfuran-2-yl)methylidenehydrazinylidene]-1-pyridin-4-ylindol-2-one
• 化学式: C₁₉H₁₄N₄O₂
• 分子量: 330.3
• InChiKey: WQGDNKJWPHVPAZ-DFLYITSRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  71.1
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Interaction inhibitors of tcf-4 with beta-catenin
  申请人：——

  公开号：US20040204477A1

  公开（公告）日：2004-10-14

  A compound of formula (I) is provided which is able to interact with &bgr;-catenin/TCF-4 binding site, having a structure essentially equivalent to a pharmacophore (IA), as herein described.

  提供了一种化合物，其化学式为(I)，能够与β-连环蛋白/TCF-4结合位点相互作用，其结构基本上等同于药效团(IA)，如本文所述。
• METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION
  申请人：IFOM Fondazione Istituto Firc di Oncologia Molecolare

  公开号：EP3145547A1

  公开（公告）日：2017-03-29
• METHODS FOR DIAGNOSING AND TREATING PELVIC PAIN DISORDERS VIA BETA-CATENIN
  申请人：Reeder Jay E.

  公开号：US20100292170A1

  公开（公告）日：2010-11-18

  Methods for diagnosing a pelvic pain disorder that include analyzing samples for increased levels and/or nuclear accumulation of beta-catenin, which indicates presence of the pelvic pain disorder, particularly interstitial cystitis. Therapeutic treatment of a pelvic pain disorder, particularly interstitial cystitis, includes the administration to a patient of an effective amount of an inhibitor of beta-catenin activity. This can be carried out by direct administration of the therapeutic agent or via gene therapy.
• US8415108B2
  申请人：——

  公开号：US8415108B2

  公开（公告）日：2013-04-09
• [EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION<br/>[FR] MÉTHODES ET COMPOSITIONS DE TRAITEMENT DE MALFORMATION VASCULAIRE
  申请人：IFOM FOND ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE

  公开号：WO2015155335A1

  公开（公告）日：2015-10-15

  An inhibitor of Wnt/β-catenin signaling for use in the treatment and/or prevention of a pathology characterized by vascular malformation. The inhibitor may be a small molecule, a protein, a peptide or an antisense nucleic acid. The invention also relates to pharmaceutical compositions and to method of treatment.